NCT01642446

Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension

A Randomized Control Clinical Trial Between Precise Hepatectomy and Combined Interventional Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 160 (actual)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

There is no consensus about the optimal treatment of hepatocellular carcinoma (HCC) with cirrhotic portal hypertension, While this group of patients are classified as hepatectomy contraindication according to guidelines from National Comprehensive Cancer Network (NCCN) and American Association for the Study of Liver Diseases (AASLD). With improvement of surgical technique, preoperative evaluation, and perioperative management,especially the Precise Hepatectomy Technique, more and more studies confirmed the safety of surgical intervention to hepatocellular carcinoma (HCC) patients with cirrhotic portal hypertension.However, most of the previous studies were either retrospective or with small samples. The investigators project is a prospective randomized controlled trial, planning to compare the safety, efficacy and quality of life between precise hepatectomy and combined interventional treatment on hepatocellular carcinoma (HCC) with cirrhotic portal hypertension, to make a further understanding of optimal strategy.

Conditions

• Hepatocellular Carcinoma(HCC)
• Cirrhotic Portal Hypertension

Interventions

Type	Name	Description
PROCEDURE	Precise hepatectomy	Precise hepatectomy
OTHER	Combined intervention (chemoembolization/ablation)	transcatheter hepatic arterial chemoembolization and/or ablation

Timeline

• Start date: 2013-01-01
• Primary completion: 2018-12-30
• Completion: 2021-08-30
• First posted: 2012-07-17
• Last updated: 2021-09-27

Locations

1 site across 1 country: China